BR112022010319A2 - Uso de bi853520 no tratamento de câncer - Google Patents

Uso de bi853520 no tratamento de câncer

Info

Publication number
BR112022010319A2
BR112022010319A2 BR112022010319A BR112022010319A BR112022010319A2 BR 112022010319 A2 BR112022010319 A2 BR 112022010319A2 BR 112022010319 A BR112022010319 A BR 112022010319A BR 112022010319 A BR112022010319 A BR 112022010319A BR 112022010319 A2 BR112022010319 A2 BR 112022010319A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
methyl
inhibitor
kras
Prior art date
Application number
BR112022010319A
Other languages
English (en)
Inventor
Wang Zaiqi
Zhang Jiangwei
Jiang Jun
Zhang Baoyuan
Original Assignee
Inxmed Nanjing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inxmed Nanjing Co Ltd filed Critical Inxmed Nanjing Co Ltd
Publication of BR112022010319A2 publication Critical patent/BR112022010319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

USO DE BI853520 NO TRATAMENTO DE CÂNCER. A presente invenção se refere a um método para tratar um tumor com uma mutação do KRAS. No método, é usado um composto 2-fluoro-5-metóxi-4-[(4-(2-metil-3-oxo-2,3-di-hidro-1H-isoindol-4-oxi)-5-trifluorometil-pirimidin-2-il)amino]-N-(1-metil-piperidin-4-il)benzamida ou um sal farmaceuticamente aceitável do mesmo, que pode ser administrado sozinho ou em combinação com um inibidor de KRAS e/ou um inibidor de MEK.
BR112022010319A 2019-11-28 2020-11-27 Uso de bi853520 no tratamento de câncer BR112022010319A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911191139 2019-11-28
CN202011287049 2020-11-17
PCT/CN2020/132244 WO2021104454A1 (zh) 2019-11-28 2020-11-27 Bi853520在癌症治疗中的用途

Publications (1)

Publication Number Publication Date
BR112022010319A2 true BR112022010319A2 (pt) 2022-08-16

Family

ID=76129165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010319A BR112022010319A2 (pt) 2019-11-28 2020-11-27 Uso de bi853520 no tratamento de câncer

Country Status (12)

Country Link
US (2) US20230000867A1 (pt)
EP (1) EP4066837A4 (pt)
JP (1) JP2023504460A (pt)
KR (1) KR20220107229A (pt)
CN (1) CN114728005A (pt)
AU (1) AU2020390236A1 (pt)
BR (1) BR112022010319A2 (pt)
CA (1) CA3159860A1 (pt)
MX (1) MX2022006402A (pt)
PE (1) PE20230180A1 (pt)
TW (1) TW202133852A (pt)
WO (1) WO2021104454A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4066837A4 (en) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN THE TREATMENT OF CANCER
TW202206425A (zh) * 2020-08-03 2022-02-16 大陸商應世生物科技（南京）有限公司 化合物的固體形式
KR20230016158A (ko) * 2021-07-22 2023-02-01 국립암센터 Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024051679A1 (zh) * 2022-09-05 2024-03-14 应世生物科技(南京)有限公司 Fak抑制剂及egfr-tki的药物组合及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US8940486B2 (en) 2010-01-12 2015-01-27 Siemens Healthcare Diagnostics Inc. Oligonucleotides and methods for detecting KRAS and PIK3CA mutations
EP2968294B1 (en) * 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
MX2018000288A (es) * 2015-06-29 2018-11-09 Verastem Inc Composiciones terapeuticas, combinaciones y metodos de uso.
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
EP4062914A4 (en) * 2019-11-18 2024-01-17 Inxmed Nanjing Co Ltd USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
EP4066837A4 (en) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
PE20230180A1 (es) 2023-02-01
US20230372340A1 (en) 2023-11-23
KR20220107229A (ko) 2022-08-02
CN114728005A (zh) 2022-07-08
MX2022006402A (es) 2022-06-24
JP2023504460A (ja) 2023-02-03
CA3159860A1 (en) 2021-06-03
AU2020390236A2 (en) 2022-07-21
AU2020390236A1 (en) 2022-07-14
US20230000867A1 (en) 2023-01-05
EP4066837A1 (en) 2022-10-05
EP4066837A4 (en) 2023-12-06
TW202133852A (zh) 2021-09-16
WO2021104454A1 (zh) 2021-06-03

Similar Documents

Publication Publication Date Title
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112021010715A2 (pt) Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA202190630A1 (ru) Способы комбинированной терапии
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
NZ756754A (en) Combination therapy for the treatment or prevention of tumours
MX2023007192A (es) Inhibidores de prmt5.
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
HK1147098A1 (en) Deuterated etravirine
PT2139483E (pt) Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
PH12016502353A1 (en) Pharmaceutical composition
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EA202190749A1 (ru) Способы комбинированной терапии
MX2021011928A (es) Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras.
TW201613577A (en) Pharmaceutical combinations
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.